The graphs seem to show that the curves were gradually separating with time. So the chances are they would have continued to do so. Another year might have bveen enough.

It would have been smart if the company had kept the patients on their treatments but still blinded and under clinical supervision while the results were being analysed, so there would have been the option of extending the trial for another year or so should the FDA request it.